January 16, 2015

The company is incorporated as Apotheca Therapeutics, Inc.

October 29, 2015

Actuate forms a Scientific Advisory Board.



March 29, 2016

Food and Drug Administration grants 9-ING-41 an orphan drug designation for the treatment of glioblastoma.



March 31, 2017

Actuate technologies are featured in the Molecular Pathways section of the journal Clinical Cancer Research.

August 18, 2017

FDA grants 9-ING-41 an additional orphan drug designation for the treatment of neuroblastoma.



February 15, 2018

The FDA accepts Actuate’s IND application for 9-ING-41 with clearance to proceed with clinical study in patients with advanced cancers.

December 17, 2018

Actuate treats first patient in Phase 1 / 2 Clinical Study of 9-ING-41 in patients with refractory cancers.



July 31, 2020

Actuate announces initiation of Phase 2 clinical study in pancreatic cancer.



August 4, 2021

Actuate announces FDA fast track designation for 9-ING-41 in the treatment of pancreatic cancer.

October 27, 2021

Actuate announces the primary endpoint was met in the 9-ING-41 Phase 2 study in pancreatic cancer.



February 7, 2022

Actuate announces of a multicenter randomized trial for elraglusib plus FOLFIRONOX as first line therapy for advanced pancreatic cancer.